Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Available at: www.ginasthma.org.www.ginasthma.org
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Available at: www.ginasthma.org.www.ginasthma.org
Bousquet J., Mantzouranis E., Cruz A.A., AïtKhaled N., Baena-Cagnani C.E., Bleecker E.R., Brightling C.E., Burney P., Bush A., Busse W.W., Casale T.B., Chan-Yeung M., Chen R., Chowdhury B., Chung K.F., Dahl R., Drazen J.M., Fabbri L.M., Holgate S.T., Kauffmann F., Haahtela T., Khaltaev N., Kiley J.P., Masjedi M.R., Mohammad Y., O’Byrne P., Partridge M.R., Rabe K.F., Togias A., van Weel C., Wenzel S., Zhong N., Zuberbier T. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926-938. doi: 10.1016/j.jaci.2010.07.019..
DOI: 10.1016/j.jaci.2010.07.019
Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J., Adcock I.M., Bateman E.D., Bel E.H., Bleecker E.R., Boulet L.P., Brightling C., Chanez P., Dahlen S.E., Djukanovic R., Frey U., Gaga M., Gibson P., Hamid Q., Jajour N.N., Mauad T., Sorkness R.L., Teague W.G. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-373. doi: 10.1183/09031936.00202013..
DOI: 10.1183/09031936.00202013
Aaron S.D., Vandemheen K.L., FitzGerald J.M., Ainslie M., Gupta S., Lemière C., Field S.K., McIvor R.A., Hernandez P., Mayers I., Mulpuru S., Alvarez G.G., Pakhale S., Mallick R., Boulet L.P. Canadian Respiratory Research Network. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317(3):269- 279. doi: 10.1001/jama.2016.19627..
DOI: 10.1001/jama.2016.19627
GINA. Difficult-to-treat & severe asthma in adolescent and adult patients. Diagnosis and Management. V2.0 April 2019. Available at: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthmaPocket-Guide-v2.0-wms-1.pdf.https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthmaPocket-Guide-v2.0-wms-1.pdf
GINA. Difficult-to-treat & severe asthma in adolescent and adult patients. Diagnosis and Management. V2.0 April 2019. Available at: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthmaPocket-Guide-v2.0-wms-1.pdf.https://ginasthma.org/wp-content/
Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011;(6):87–93. doi: 10.18093/0869-0189-2011-0-6-87-93..
DOI: 10.18093/0869-0189-2011-0-6-87-93
Харитонс М.А., Рамазанова К.А. Современные представления о лечении бронхиальной астмы. Терра Медика Нова. 2001;(1). Режим доступа: https://medi.ru/info/6513.https://medi.ru/info/6513
Харитонс М.А., Рамазанова К.А. Современные представления о лечении бронхиальной астмы. Терра Медика Нова. 2001;(1). Режим доступа: https://medi.ru/info/6513.https://medi.ru/
Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А., Михайлова И.Э., Наумова О.С. Клинические фенотипы бронхиальной астмы у подростков: трудности диагностики и терапии. Лечащий врач. 2015;(4):20. Режим доступа: https://www.lvrach.ru/2015/04/15436197.https://www.lvrach.ru/2015/04/15436197
Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н., Перфилова И.А., Михайлова И.Э., Наумова О.С. Клинические фенотипы бронхиальной астмы у подростков: трудности диагностики и терапии. Лечащий врач. 2015;(4):20. Режим доступа: https://www.lvrach.ru/2015/04/15436197.https://www.lvrach.ru/2015/04/15436197
Куличенко Т.В. Омализумаб у детей с бронхиальной астмой: показания к применению. Педиатрическая фармакология. 2007;4(6):51– 55. Режим доступа: https://elibrary.ru/item.asp?id=11530603.https://elibrary.ru/item.asp?id=11530603
Куличенко Т.В. Омализумаб у детей с бронхиальной астмой: показания к применению. Педиатрическая фармакология. 2007;4(6):51– 55. Режим доступа: https://elibrary.ru/item.asp?id=11530603.https://elibrary.ru/item.asp?id=11530603
Hekking P.P., Wener R.R., Amelink M., Zwinderman A.H., Bouvy M.L., Bel E.H. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902. doi: 10.1016/j.jaci.2014.08.042..
DOI: 10.1016/j.jaci.2014.08.042
Schatz M., Hsu J.W., Zeiger R.S., Chen W., Dorenbaum A., Chipps B.E., Haselkorn T. Phenotypes determined by cluster analysis in severe difficult-to treat asthma. J Allergy Clin Immunol. 2014;133(6):1549-1556. doi: 10.1016/j.jaci.2013.10.006..
DOI: 10.1016/j.jaci.2013.10.006
Newby C., Heaney L.G., Menzies-Gow A., Niven R.M., Mansur A., Bucknall C., Chaudhuri R., Thompson J., Burton P., Brightling C. British Thoracic Society Severe Refractory Asthma Network. Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability. PLoS One. 2014;9(7):e102987. doi: 10.1371/journal.pone.0102987..
DOI: 10.1371/journal.pone.0102987
Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107-1119. doi: 10.1016/S0140-6736(08)61452-X..
DOI: 10.1016/S0140-6736(08)61452-X
Woodruff P.G., Modrek B., Choy D.F., Jia G., Abbas A.R., Ellwanger A., Koth L.L., Arron J.R., Fahy J.V. T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009;180(5):388-395. doi: 10.1164/rccm.200903-0392OC..
DOI: 10.1164/rccm.200903-0392OC
Bhakta N.R., Woodruff P.G. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev. 2011;242(1):220-232. doi: 10.1111/j.1600-065X.2011.01032.x..
DOI: 10.1111/j.1600-065X.2011.01032.x
Сергеева Г.Р., Емельянов А.В., Коровина О.В., Знахуренко А.А., Лешенкова Е.В., Козырева Л.В., Асатиани Н. Тяжелая бронхиальная астма: характеристика пациентов в клинической практике. Терапевтический архив. 2015;87(12):22-27. doi: 10.17116/terarkh2015871226-31..
DOI: 10.17116/terarkh2015871226-31
Schleich F., Brusselle G., Louis R., Vandenplas O., Michils A., Pilette C., Peche R., Manise M., Joos G. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723-1732. doi: 10.1016/j.rmed.2014.10.007..
DOI: 10.1016/j.rmed.2014.10.007
Bai T.R., Vonk J.M., Postma D.S., Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452-456. doi: 10.1183/09031936.00165106..
DOI: 10.1183/09031936.00165106
Hancox R.J., Pavord I.D., Sears M.R. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018;51(4). pii: 1702536. doi: 10.1183/13993003.02536-2017..
DOI: 10.1183/13993003.02536-2017
Fitzpatrick A.M. Severe asthma in children: lessons learned and future directions. J Allergy Clin Immunol Pract. 2016;4(1):11-9; quiz 20-1. doi: 10.1016/j.jaip.2015.10.008..
DOI: 10.1016/j.jaip.2015.10.008
Westerhof G.A., Korevaar D.A., Amelink M., de Nijs S.B., de Groot J.C., Wang J., Weersink E.J., ten Brinke A., Bossuyt P.M., Bel E.H. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J. 2015;46(3):688-696. doi: 10.1183/09031936.00012415..
DOI: 10.1183/09031936.00012415
Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., Marshall R.P., Bradding P., Green R.H., Wardlaw A.J., Pavord I.D. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-984. doi: 10.1056/NEJMoa0808991..
DOI: 10.1056/NEJMoa0808991
Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., Ortega H., Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-659. doi: 10.1016/S0140-6736(12)60988-X..
DOI: 10.1016/S0140-6736(12)60988-X
Castro M., Mathur S., Hargreave F., Boulet L.P., Xie F., Young J., Wilkins H.J., Henkel T., Nair P. Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-1132. doi: 10.1164/rccm.201103-0396OC..
DOI: 10.1164/rccm.201103-0396OC
Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., Wang L., Kirkesseli S., Rocklin R., Bock B., Hamilton J., Ming J.E., Radin A., Stahl N., Yancopoulos G.D., Graham N., Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455-2466. doi: 10.1056/ NEJMoa1304048..
DOI: 10.1056/ NEJMoa1304048
Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., Wang L., Kirkesseli S., Rocklin R., Bock B., Hamilton J., Ming J.E., Radin A., Stahl N., Yancopoulos G.D., Graham N., Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455-2466. doi: 10.1056/ NEJMoa1304048..
DOI: 10.1056/NEJMoa1304048
Castro M., Wenzel S.E., Bleecker E.R., Pizzichini E., Kuna P., Busse W.W., Gossage D.L., Ward C.K., Wu Y., Wang B., Khatry D.B., van der Merwe R., Kolbeck R., Molfino N.A., Raible D.G. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2..
DOI: 10.1016/S2213-2600(14)70201-2
Castro M., Corren J., Pavord I.D., Maspero J., Wenzel S., Rabe K.F., Busse W.W., Ford L., Sher L., FitzGerald J.M., Katelaris C., Tohda Y., Zhang B., Staudinger H., Pirozzi G., Amin N., Ruddy M., Akinlade B., Khan A., Chao J., Martincova R., Graham N.M.H., Hamilton J.D., Swanson B.N., Stahl N., Yancopoulos G.D., Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-2496. doi: 10.1056/NEJMoa1804092..
DOI: 10.1056/NEJMoa1804092
Brusselle G.G., Maes T., Bracke K.R. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19(8):977-979. doi: 10.1038/nm.3300..
DOI: 10.1038/nm.3300
Fajt M.L., Wenzel S.E. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017 Jan;9(1):3-14. doi: 10.4168/aair.2017.9.1.3..
DOI: 10.4168/aair.2017.9.1.3
Israel E., Reddel H.K. Severe and Difficult-toTreat Asthma in Adults. N Engl J Med. 2017;377(10):965-976. doi: 10.1056/NEJMra1608969..
DOI: 10.1056/NEJMra1608969
Kau A.L., Korenblat P.E. Anti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes. Curr Opin Allergy Clin Immunol. 2014;14(6):570–575. doi: 10.1097/ACI.0000000000000108..
DOI: 10.1097/ACI.0000000000000108
Gandhi N.A., Bennett B.L., Graham N.M., Pirozzi G., Stahl N., Vancopoulos G.D. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35– 50. doi: 10.1038/nrd4624..
DOI: 10.1038/nrd4624
Coffman R.L. Converging discoveries: The first reports of il-4. Journal of immunology. 2013;190(3):847–848. Available at: https://www.jimmunol.org/content/190/3/847.https://www.jimmunol.org/content/190/3/847
Coffman R.L. Converging discoveries: The first reports of il-4. Journal of immunology. 2013;190(3):847–848. Available at: https://www.jimmunol.org/content/190/3/847.https://www.jimmunol.org/content/190/3/847
Brusselle G., Kips J., Joos G., Bluethmann H., Pauwels R. Allergen-induced airway inflammation and bronchial responsiveness in wildtype and interleukin-4-deficient mice. Am J Respir Cell Mol Biol. 1995;12(3):254–259. doi: 10.1165/ajrcmb.12.3.7873190..
DOI: 10.1165/ajrcmb.12.3.7873190
Gavett S.H., O’Hearn D.J., Karp C.L., Patel E.A., Schofield B.H., Finkelman F.D., Wills-Karp M. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol. 1997;272(2 Pt 1):L253– L261. doi: 10.1152/ajplung.1997.272.2.L253..
DOI: 10.1152/ajplung.1997.272.2.L253
Corry D.B., Folkesson H.G., Warnock M.L., Erle D.J., Matthay M.A., Wiener-Kronish J.P., Locksley R.M. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med. 1996;183(1):109–117. doi: 10.1084/jem.183.1.109..
DOI: 10.1084/jem.183.1.109
Henderson W.R. Jr., Chi E.Y., Maliszewski C.R. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol. 2000;164(2):1086–1095. doi: 10.4049/jimmunol.164.2.1086..
DOI: 10.4049/jimmunol.164.2.1086
Dabbagh K., Takeyama K., Lee H.M., Ueki I.F., Lausier J.A., Nadel J.A. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol. 1999;162(10):6233–6237. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10229869.https://www.ncbi.nlm.nih.gov/pubmed/10229869
Dabbagh K., Takeyama K., Lee H.M., Ueki I.F., Lausier J.A., Nadel J.A. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol. 1999;162(10):6233–6237. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10229869.https://www.ncbi.nlm.nih.gov/pubmed/10229869
Tepper R.I., Levinson D.A., Stanger B.Z., Campos-Torres J., Abbas A.K., Leder P. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell. 1990;62(3):457–467. doi: 10.1016/0092-8674(90)90011-3..
DOI: 10.1016/0092-8674(90)90011-3
Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., Donaldson D.D. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258–2261. doi: 10.1126/science.282.5397.2258..
DOI: 10.1126/science.282.5397.2258
Grünig G., Warnock M., Wakil A.E., Venkayya R., Brombacher F., Rennick D.M., Sheppard D., Mohrs M., Donaldson D.D., Locksley R.M., Corry D.B. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282(5397):2261–2263. doi: 10.1126/science.282.5397.2261..
DOI: 10.1126/science.282.5397.2261
Zhu Z., Homer R.J., Wang Z., Chen Q., Geba G.P., Wang J., Zhang Y., Elias J.A. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779–788. doi: 10.1172/JCI5909..
DOI: 10.1172/JCI5909
Webb D.C., McKenzie A.N., Koskinen A.M., Yang M., Mattes J., Foster P.S. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol. 2000;165(1):108– 113. doi: 10.4049/jimmunol.165.1.108..
DOI: 10.4049/jimmunol.165.1.108
Kuperman D.A., Huang X., Koth L.L., Chang G.H., Dolganov G.M., Zhu Z., Elias J.A., Sheppard D., Erle D.J. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8(8):885–889. doi: 10.1038/nm734..
DOI: 10.1038/nm734
Gour N., Wills-Karp M. IL-4 and IL-13 Signaling in Allergic Airway Disease. Cytokine. 2015;75(1):68-78. doi: 10.1016/j.cyto.2015.05.014..
DOI: 10.1016/j.cyto.2015.05.014
Gour N., Wills-Karp M. IL-4 and IL-13 Signaling in Allergic Airway Disease. Cytokine. 2015;75(1):68-78. doi: 10.1016/j.cyto.2015.05.014..
DOI: 10.1016/j. cyto.2015.05.014
Busse W.W., Maspero J.F., Rabe K.F., Papi A., Wenzel S.E., Ford L.B., Pavord I.D., Zhang B., Staudinger H., Pirozzi G., Amin N., Akinlade B., Eckert L., Chao J., Graham N.M.H., Teper A. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, ParallelGroup Study to Evaluate Dupilumab Efficacy/ Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018;35(5):737-748. doi: 10.1007/s12325-018-0702-4..
DOI: 10.1007/s12325-018-0702-4
Rabe K.F., Nair P., Brusselle G., Maspero J.F., Castro M., Sher L., Zhu H., Hamilton J.D., Swanson B.N., Khan A., Chao J., Staudinger H., Pirozzi G., Antoni C., Amin N., Ruddy M., Akinlade B., Graham N.M.H., Stahl N., Yancopoulos G.D., Teper A. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485. doi: 10.1056/NEJMoa1804093..
DOI: 10.1056/NEJMoa1804093